Performance Indicators

Performance Indicators Commentary

The diagnosis year 2020 performance indicators for the registries of the UKIACR are available here.

You can click on the various tabs to view the corresponding comparison tables. You can use the search box above the table to filter it, or click on any column in the table to sort by it (if applicable). Please read the notes under each table, as sometimes the data is not directly comparable.

A detailed commentary of the findings for each registry may be found at this link.

An Excel download of the complete results tables may be found at this link.

Old Performance Indicators Reports

Reports are also available for preceding years. Use the links below to access these reports:

2019 data - UKIACR 2021 Report on 2019 data | Commentary
2018 data - UKIACR Report 2020 | Commentary
2017 data - UKIACR Report 2019 | Commentary
2016 data - UKIACR Report 2018 | Commentary
2015 data - UKIACR Report 2017 | Commentary
2014 data - UKIACR Report 2016 | Commentary
2013 data - UKIACR Report 2015 | Commentary
2012 data - UKIACR Report 2014 | Commentary
2011 data - UKACR Report 2013.xlsx
2010 data - UKACR Report 2012.xlsm
2009 data - UKACR Report 2011.xlsm
2008 data - UKACR Report 2010.xlsm
2007 data - UKACR Report 2009.xlsm
2006 data - UKACR Report 2008.xlsm

Executive summary

Target not reached or not in line with other registries

Target attained

Show entries

Search:

Indicator	Country average (population)¹	Country average (country)¹	England	Scotland	Northern Ireland	Wales
Average of Core Patient Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with demographic information³	98.9%	97.8%	99.3%	98.3%	100.0%	93.5%
Average of Core Tumour Information Complete: Average percentage (%) of all cancers (C00-C97 ex. C44) registered with tumour information⁴	96.4%	96.3%	96.5%	96.1%	96.3%	96.1%
Bowel Screening Data: Percentage of bowel cancer (C18-C20) cases from 2019 screen detected for ages 60-69	5.8%	22.1%	0.0%	37.1%	26.6%	24.9%
Breast Screening Data: Percentage of breast cancer (C50) cases from 2019 screen detected for ages 50-64	50.5%	51.4%	50.3%	50.4%	49.7%	55.1%
Cervical Screening Data: Percentage of cervical cancer (C53) cases from 2019 screen detected for ages 25-60	20.4%	44.2%	13.5%	54.3%	63.1%	45.9%
Death Certificate Only (DCO) Rates: Percentage (%) of all cancers (C00-C97 ex. C44) registered as a DCO⁵	2.1%	1.2%	2.3%	0.6%	0.9%	0.9%
Diagnosing Hospital Known: Percentage (%) of all cancers (C00-C97 ex. C44) registered with an organisation of diagnosis	96.8%	96.8%	96.8%	95.5%	-	98.1%
Grade: Percentage (%) of all cancers (C00-C97 ex. C44) registered with a known grade	56.1%	57.3%	55.9%	57.3%	59.6%	56.5%
Microscopically Verified: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified	81.0%	80.8%	81.2%	79.2%	83.4%	79.6%
Non Specific Codes: Percentage (%) of all cancers (C00-C97 ex. C44) that are microscopically verified with non specific morphology codes	1.4%	1.1%	1.5%	0.9%	1.2%	0.9%
Registry Creep: Percentage (%) for all cancers (C00-C97 ex. C44) of 2019 registrations (extracted between 04/02/2022 and 06/05/2023) compared with registrations extracted between 22/02/2021 and 06/08/22 ⁶.	0.3%	-0.1%	0.6%	-2.9%	1.0%	0.8%
Stability: Percentage change (%) for all cancers (C00-C97 ex. C44) in 2020 compared with 2017-2019	-10.3%	-10.1%	-10.2%	-9.7%	-8.0%	-12.6%
Staging: Proportion (%) of all cases (C00-C97 ex. C44) with valid known stage registered out of all 2020 registered cancers (C00-C97 ex. C44)²	75.1%	75.8%	75.5%	66.4%	81.2%	80.0%
Treatment: Percentage (%) of all cancers (C00-C97 ex. C44) registered with any treatment	85.4%	82.0%	85.9%	86.1%	74.8%	81.2%
Zero Day Survivors: Percentage (%) of all cancers (C00-C97 ex. C44) registered with the date of death equals the date of diagnosis⁵	2.8%	1.7%	3.1%	1.2%	1.1%	1.7%

Showing 1 to 15 of 15 entries

Previous1Next

For England, Scotland, Wales and Northern Ireland.
Staging target: > 70%
Core Patient information includes name, address, postcode, sex, date of birth, ethnicity, date of death, unique health identifier
Core Tumour information includes date of diagnosis, site of primary growth, type of growth, behaviour of growth, basis of diagnosis
DCO and zero survivor rate targets: <2%
Extraction dates for last years indicators: England 04/09/2021, Scotland 22/02/2021, Northern Ireland 16/09/2021 & Wales 06/08/2022

Extraction dates for this years indicators: England 01/10/2022, Scotland 04/02/2022, Northern Ireland 09/02/2023, Wales 06/05/2023

Notation '-' denotes not available (average excludes corresponding country)

For England, 0.0% reflects the unavailability of screening data to NCRAS. NCRAS continued to work with the screening programme to try and obtain an extract to use to pilot a new method of loading screening data files on the Encore ‘waterfall’

Registrations and Timeliness

Show entries

Search:

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Northern Ireland	Wales
2017	373685	93421	311552	33080	9861	19192
2018	389608	97402	324342	34800	10066	20400
2019	392977	98244	329185	33154	10298	20340
2019 (from Previous PI)	391667	97917	327173	34132	10193	20169
No. of 2020 full cases	345882	86471	288753	30395	9273	17461
No. of 2020 not-finalised cases	206	52	171	31	0	4
Not-finalised cases	0.06	0.05	0.06	0.10	0.00	0.02
Registry creep	0.3%	-0.1%	0.6%	-2.9%	1.0%	0.8%

Showing 1 to 8 of 8 entries

Previous1Next

No. of Cases (current year) and percentage change vs. previous year (persons)

Statistically significant difference in 2020 compared to 2017-2019

No statistical significant difference in 2020 compared to 2017-2019

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	345,882 (-10.3%)	-10.1%	288753 (-10.2%)	30395 (-9.7%)	9273 (-8%)	17461 (-12.6%)
All registrations	539,773 (-14.2%)	-15.7%	449788 (-13.8%)	46591 (-15%)	15505 (-15.1%)	27889 (-18.9%)
All xnmsc 0-24	3,582 (-5.1%)	-2.3%	3043 (-5.5%)	259 (-9.2%)	108 (-5%)	172 (10.5%)
All xnmsc 25-59	78,872 (-11.7%)	-12.0%	66157 (-11.7%)	6870 (-11%)	2194 (-13.6%)	3651 (-11.7%)
All xnmsc 60-79	184,754 (-10.8%)	-10.3%	153320 (-10.8%)	16675 (-10.2%)	5062 (-6.2%)	9697 (-13.8%)
All xnmsc 80+	78,674 (-7.6%)	-7.9%	66233 (-7.4%)	6591 (-7.1%)	1909 (-5.8%)	3941 (-11.2%)
Basal cell carcinoma	84241 (-26.8%)	-29.2%	71364 (-26.1%)	5827 (-29.1%)	2036 (-28.3%)	5014 (-33%)
Bladder	10,250 (-2.1%)	-5.5%	8752 (-1.4%)	800 (-2.4%)	218 (-7.8%)	480 (-10.6%)
Brain and CNS	5,439 (-5.5%)	-6.1%	4585 (-5.1%)	411 (-12.1%)	149 (-5.3%)	294 (-1.8%)
Breast	48,204 (-15.2%)	-13.3%	40192 (-15.6%)	4312 (-11.9%)	1363 (-9.5%)	2337 (-16.3%)
Breast in situ	5,853 (-30.8%)	-31.7%	5099 (-30.4%)	326 (-32.6%)	194 (-23.4%)	234 (-40.3%)
Cervix	2,840 (-12.8%)	-15.3%	2371 (-11.8%)	266 (-18.2%)	73 (-12.7%)	130 (-18.4%)
Cervix in situ	19,525 (-22.2%)	-33.6%	16868 (-18.4%)	1152 (-45.2%)	594 (-35.7%)	911 (-35.3%)
CUP	7,717 (-4.4%)	0.0%	6179 (-6%)	798 (2.1%)	181 (-0.7%)	559 (4.7%)
Haematology	30,707 (-9.5%)	-9.6%	26214 (-9.5%)	2321 (-9.2%)	817 (-9.3%)	1355 (-10.6%)
Head and Neck	12,213 (-4.3%)	-9.3%	10020 (-3.2%)	1228 (-5.3%)	306 (-17.5%)	659 (-11.1%)
HPB	20,396 (2.3%)	3.4%	17040 (2.2%)	1770 (2.7%)	556 (9.3%)	1030 (-0.7%)
Kidney	12,397 (-8.9%)	-12.9%	10444 (-8.1%)	1058 (-11.5%)	296 (-21.8%)	599 (-10.3%)
Lower GI	44,420 (-6.6%)	-9.9%	37315 (-5.2%)	3632 (-15.7%)	1176 (-8.1%)	2297 (-10.7%)
Melanoma of skin	14,741 (-15.9%)	-16.9%	12477 (-15.8%)	1183 (-14.5%)	324 (-18.3%)	757 (-18.8%)
Other Female Genitals	18,074 (-6%)	-8.8%	15088 (-5.6%)	1583 (-5.3%)	449 (-17%)	954 (-7.3%)
Other invasive cancer	10,990 (-7.2%)	-6.6%	9173 (-7.6%)	998 (-4%)	288 (-10.6%)	531 (-4.2%)
Other non-melanoma skin cancer	1984 (-2.8%)	-2.7%	1647 (-1.9%)	135 (-22.7%)	119 (14.1%)	83 (-0.4%)
Other tumours	44,363 (-17.7%)	-22.6%	35185 (-15.9%)	5141 (-21.8%)	2272 (-22.1%)	1765 (-30.8%)
Prostate	42,895 (-22.1%)	-16.8%	36016 (-23.1%)	3394 (-13.7%)	1224 (-5%)	2261 (-25.3%)
Squamous cell carcinoma	37925 (-2.6%)	-3.8%	30872 (-2.7%)	3615 (1.3%)	1017 (-10.7%)	2421 (-3.2%)
Thyroid & other endocrine glands	3,923 (-11.7%)	-15.5%	3379 (-10.6%)	274 (-20.1%)	160 (1.7%)	110 (-32.9%)
Trachea, Bronchus & Lung	45,801 (-7%)	-6.8%	37237 (-6.7%)	4933 (-8.9%)	1316 (-3%)	2315 (-8.3%)
Upper GI	14,875 (-6.6%)	-7.7%	12271 (-6.4%)	1434 (-5.7%)	377 (-7.8%)	793 (-11%)

Showing 1 to 29 of 29 entries

Previous1Next

Percentage (%) of death certificate only cases (persons) for 2020
A statistic highlighted in red means that the target was not reached or was not in line with other registries

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	2.1%	1.2%	2.3%	0.6%	0.9%	0.9%
All registrations	1.5%	0.8%	1.7%	0.4%	0.6%	0.6%
All xnmsc 0-24	0.1%	0.0%	0.1%	0.0%	0.0%	0.0%
All xnmsc 25-59	0.3%	0.1%	0.3%	0.1%	0.0%	0.1%
All xnmsc 60-79	1.0%	0.6%	1.2%	0.3%	0.4%	0.4%
All xnmsc 80+	6.4%	3.9%	7.1%	2.0%	3.5%	3.0%
Bladder	3.4%	1.4%	3.9%	0.4%	0.0%	1.5%
Brain and CNS	3.1%	1.0%	3.7%	0.0%	0.0%	0.3%
Breast	0.7%	0.5%	0.8%	0.3%	0.7%	0.3%
Breast in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cervix	0.7%	0.6%	0.8%	0.4%	1.4%	0.0%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CUP	14.0%	8.2%	16.2%	3.0%	6.6%	6.8%
Haematology	2.0%	1.1%	2.3%	0.4%	0.7%	0.9%
Head and Neck	0.9%	0.6%	1.0%	0.1%	1.3%	0.2%
HPB	3.8%	1.5%	4.5%	0.6%	0.4%	0.5%
Kidney	2.0%	0.7%	2.3%	0.1%	0.0%	0.5%
Lower GI	1.7%	0.9%	1.9%	0.4%	0.9%	0.6%
Melanoma of skin	0.2%	0.2%	0.2%	0.0%	0.3%	0.4%
Other Female Genitals	1.7%	1.5%	1.9%	0.8%	2.2%	1.0%
Other invasive cancer	4.3%	4.1%	4.3%	5.3%	3.5%	3.2%
Other tumours	1.7%	0.8%	2.0%	0.3%	0.4%	0.6%
Prostate	1.3%	0.8%	1.4%	0.1%	0.9%	0.9%
Thyroid & other endocrine glands	0.7%	0.4%	0.7%	0.0%	0.0%	0.9%
Trachea, Bronchus & Lung	2.2%	1.1%	2.6%	0.4%	0.6%	0.6%
Upper GI	1.9%	1.3%	2.0%	1.2%	1.1%	1.0%

Showing 1 to 26 of 26 entries

Previous1Next

Percentage (%) of zero survival cases (persons)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	2.8%	1.7%	3.1%	1.2%	1.1%	1.7%
All registrations	2.0%	1.2%	2.2%	0.8%	0.7%	1.1%
All xnmsc 0-24	0.3%	0.4%	0.3%	0.4%	0.9%	0.0%
All xnmsc 25-59	0.6%	0.4%	0.7%	0.5%	0.0%	0.3%
All xnmsc 60-79	1.7%	1.1%	1.9%	0.7%	0.5%	1.1%
All xnmsc 80+	7.6%	4.9%	8.3%	3.2%	3.8%	4.3%
Bladder	4.1%	2.0%	4.6%	1.4%	0.0%	2.1%
Brain and CNS	3.7%	1.6%	4.3%	0.7%	0.7%	0.7%
Breast	0.8%	0.6%	0.9%	0.4%	0.7%	0.4%
Breast in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Cervix	0.9%	0.9%	1.0%	0.4%	1.4%	0.8%
Cervix in situ	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CUP	16.5%	10.0%	18.8%	6.3%	5.5%	9.5%
Haematology	2.7%	1.5%	3.0%	0.9%	0.7%	1.5%
Head and Neck	1.1%	0.9%	1.3%	0.2%	1.6%	0.3%
HPB	5.3%	2.4%	6.1%	1.2%	0.5%	1.7%
Kidney	2.9%	1.6%	3.3%	0.8%	0.3%	1.8%
Lower GI	2.5%	1.5%	2.7%	0.9%	0.9%	1.4%
Melanoma of skin	0.3%	0.2%	0.3%	0.0%	0.3%	0.4%
Other Female Genitals	2.2%	1.8%	2.3%	1.2%	2.2%	1.4%
Other invasive cancer	5.5%	5.3%	5.4%	7.1%	3.5%	5.3%
Other tumours	2.0%	1.1%	2.4%	0.4%	0.5%	1.0%
Prostate	1.5%	1.0%	1.6%	0.3%	1.1%	1.1%
Thyroid & other endocrine glands	1.0%	0.7%	1.2%	0.0%	0.0%	1.8%
Trachea, Bronchus & Lung	3.5%	2.0%	4.0%	1.4%	1.0%	1.7%
Upper GI	3.0%	2.3%	3.1%	1.9%	1.3%	2.8%

Showing 1 to 26 of 26 entries

Previous1Next

Percentage (%) of microscopically verified cases (persons)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	81.0%	80.8%	81.2%	79.2%	83.4%	79.6%
All registrations	86.4%	86.2%	86.5%	85.4%	86.9%	86.0%
All xnmsc 0-24	91.6%	92.1%	91.4%	96.1%	92.6%	88.4%
All xnmsc 25-59	94.9%	95.7%	94.7%	95.7%	97.1%	95.2%
All xnmsc 60-79	85.4%	85.0%	85.6%	83.2%	87.3%	83.9%
All xnmsc 80+	56.3%	54.8%	56.9%	51.1%	57.1%	54.2%
Bladder	85.5%	86.3%	85.4%	84.6%	89.0%	86.3%
Brain and CNS	63.9%	58.3%	65.1%	66.4%	55.7%	45.9%
Breast	97.6%	98.0%	97.5%	98.2%	98.5%	97.6%
Breast in situ	99.9%	100.0%	99.9%	100.0%	100.0%	100.0%
Cervix	97.1%	97.5%	97.0%	98.1%	98.6%	96.2%
Cervix in situ	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
CUP	37.6%	39.1%	37.6%	38.3%	46.4%	34.0%
Haematology	83.5%	88.9%	82.2%	92.8%	92.4%	88.3%
Head and Neck	96.1%	96.0%	96.1%	96.4%	95.4%	96.1%
HPB	49.2%	48.2%	50.1%	41.0%	59.2%	42.4%
Kidney	67.2%	69.4%	66.6%	70.4%	72.3%	68.1%
Lower GI	84.7%	84.7%	84.9%	82.0%	87.8%	84.1%
Melanoma of skin	99.3%	99.3%	99.3%	99.9%	98.8%	99.1%
Other Female Genitals	92.7%	91.9%	93.0%	91.4%	91.5%	91.5%
Other invasive cancer	82.1%	79.9%	83.3%	72.4%	86.8%	77.0%
Other tumours	85.1%	84.4%	84.8%	90.7%	81.1%	81.2%
Prostate	82.4%	82.6%	82.5%	81.4%	83.8%	82.6%
Thyroid & other endocrine glands	95.8%	96.2%	95.6%	97.1%	99.4%	92.7%
Trachea, Bronchus & Lung	63.5%	62.1%	64.2%	58.6%	62.6%	62.9%
Upper GI	88.7%	89.0%	88.8%	87.7%	92.8%	86.8%

Showing 1 to 26 of 26 entries

Previous1Next

Percentage (%) of non-specificity of morphology codes for cases which are microscopically verified

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All registrations	1.1%	0.9%	1.1%	0.6%	1.4%	0.6%
All xnmsc 0-24	1.2%	0.4%	1.4%	0.0%	0.0%	0.0%
All xnmsc 25-59	1.0%	0.8%	1.0%	0.6%	0.8%	0.7%
All xnmsc 60-79	1.2%	1.0%	1.3%	0.8%	1.2%	0.8%
All xnmsc 80+	2.6%	2.0%	2.7%	1.6%	2.1%	1.6%
Bladder	1.0%	0.7%	1.1%	0.3%	1.0%	0.5%
Brain and CNS	1.2%	0.3%	1.4%	0.0%	0.0%	0.0%
Breast	1.2%	1.2%	1.2%	0.5%	1.9%	1.1%
Breast in situ	0.2%	0.2%	0.2%	0.0%	0.5%	0.0%
Cervix	0.8%	0.3%	0.9%	0.4%	0.0%	0.0%
Cervix in situ	1.2%	0.4%	1.4%	0.0%	0.0%	0.0%
CUP	15.1%	15.4%	15.5%	13.7%	23.8%	8.4%
Haematology	0.5%	0.4%	0.5%	0.4%	0.3%	0.5%
Head and Neck	0.9%	0.8%	0.9%	0.9%	1.4%	0.2%
HPB	5.5%	4.5%	5.8%	4.3%	4.3%	3.7%
Kidney	1.5%	0.7%	1.7%	0.8%	0.0%	0.2%
Lower GI	1.1%	0.7%	1.2%	0.4%	0.6%	0.8%
Melanoma of skin	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Other Female Genitals	1.0%	0.5%	1.2%	0.6%	0.0%	0.1%
Other invasive cancer	0.9%	0.9%	0.9%	0.6%	1.2%	0.7%
Other tumours	2.1%	2.2%	2.1%	1.1%	5.0%	0.8%
Prostate	0.7%	0.3%	0.8%	0.1%	0.0%	0.5%
Thyroid & other endocrine glands	1.8%	1.1%	2.0%	0.8%	0.6%	1.0%
Trachea, Bronchus & Lung	2.3%	1.7%	2.5%	1.6%	1.6%	1.2%
Upper GI	1.1%	0.9%	1.2%	0.7%	0.6%	1.0%

Showing 1 to 25 of 25 entries

Previous1Next

Mortality : Incidence ratios (2020)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	0.48	0.50	0.48	0.53	0.49	0.52
All registrations	0.32	0.33	0.31	0.36	0.30	0.34
All xnmsc 0-24	0.12	0.12	0.12	0.13	0.12	0.10
All xnmsc 25-59	0.25	0.26	0.24	0.28	0.24	0.28
All xnmsc 60-79	0.45	0.47	0.44	0.51	0.47	0.48
All xnmsc 80+	0.82	0.85	0.81	0.88	0.85	0.85
Bladder	0.55	0.58	0.54	0.58	0.59	0.61
Brain and CNS	0.82	0.85	0.81	0.87	0.85	0.86
Breast	0.24	0.24	0.24	0.23	0.23	0.27
Breast in situ	0.00	0.00	0.00	0.00	0.00	0.00
Cervix	0.31	0.33	0.30	0.41	0.23	0.38
Cervix in situ	0.00	0.00	0.00	0.00	0.00	0.00
CUP	1.24	1.15	1.28	1.06	1.20	1.06
Haematology	0.43	0.46	0.42	0.47	0.44	0.51
Head and Neck	0.35	0.39	0.35	0.40	0.47	0.34
HPB	0.86	0.89	0.84	0.94	0.87	0.91
Kidney	0.35	0.40	0.34	0.42	0.46	0.37
Lower GI	0.41	0.43	0.40	0.50	0.37	0.44
Melanoma of skin	0.16	0.17	0.16	0.15	0.18	0.18
Other Female Genitals	0.41	0.45	0.40	0.46	0.48	0.44
Other invasive cancer	0.81	0.81	0.81	0.78	0.82	0.81
Other tumours	0.09	0.08	0.10	0.07	0.05	0.12
Prostate	0.29	0.28	0.29	0.31	0.23	0.31
Thyroid & other endocrine glands	0.14	0.16	0.14	0.17	0.10	0.24
Trachea, Bronchus & Lung	0.73	0.77	0.72	0.79	0.79	0.77
Upper GI	0.81	0.86	0.79	0.89	0.89	0.88

Showing 1 to 26 of 26 entries

Previous1Next

Completeness of the dataset (%) - demographics and diagnostic details

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
Anniversary (diagnosis) date	100.0%	100.0%	100.0%	100.0%	100.0%	99.9%
Basis of diagnosis	98.7%	99.5%	98.5%	100.0%	99.8%	99.8%
Behaviour of growth	99.7%	99.5%	99.8%	99.7%	98.8%	99.5%
Date of birth	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Diagnosis with hospital	96.8%	96.8%	96.8%	95.5%	-	98.1%
Ethnicity	92.2%	79.3%	94.9%	88.1%	-	54.7%
Patient's address	99.9%	100.0%	99.9%	100.0%	100.0%	100.0%
Patient's name	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Postcode	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Sex	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Site of primary growth	97.7%	97.4%	97.8%	97.1%	98.0%	96.7%
Type of growth	86.0%	85.0%	86.3%	83.9%	85.0%	84.8%
Unique health identifier	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

Showing 1 to 13 of 13 entries

Previous1Next

% of all cancer cases (xnmsc)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
No Treatment	4.9%	10.7%	3.6%	13.8%	25.2%	0.2%
Stage I and II patients receiving any treatment (%)	94.6%	92.2%	94.8%	91.6%	83.2%	99.2%
Treatment	85.4%	82.0%	85.9%	86.1%	74.8%	81.2%

Showing 1 to 3 of 3 entries

Previous1Next

% of Cases treated with Surgery

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	44.8%	40.3%	46.2%	36.3%	38.6%	40.1%
All xnmsc 0-24	48.3%	45.5%	48.6%	47.5%	30.6%	55.2%
All xnmsc 25-59	62.2%	58.4%	63.2%	57.3%	52.8%	60.5%
All xnmsc 60-79	44.9%	39.5%	46.6%	34.8%	37.7%	38.8%
All xnmsc 80+	27.1%	23.7%	28.3%	17.6%	25.2%	23.5%
Bladder	81.1%	81.9%	81.1%	78.3%	85.8%	82.5%
Brain and CNS	45.3%	42.0%	45.9%	48.7%	37.6%	36.1%
Breast	70.8%	71.8%	70.5%	72.2%	73.7%	70.8%
Breast in situ	82.1%	83.2%	81.8%	86.2%	83.0%	81.6%
Cervix	57.1%	45.3%	60.1%	42.1%	32.9%	46.2%
Cervix in situ	85.5%	67.1%	88.1%	96.4%	12.8%	71.4%
CUP	8.4%	7.0%	9.5%	2.3%	12.7%	3.6%
Haematology	5.5%	3.9%	5.8%	3.7%	0.5%	5.6%
Head and Neck	49.0%	42.3%	51.3%	37.2%	39.9%	41.0%
HPB	30.2%	24.5%	32.8%	7.5%	35.8%	22.0%
Kidney	48.2%	46.7%	49.2%	39.5%	54.7%	43.6%
Lower GI	63.1%	62.2%	64.0%	52.1%	69.9%	62.9%
Melanoma of skin	94.3%	87.0%	94.9%	96.4%	61.1%	95.6%
Non-Melanoma Skin Cancer	47.6%	55.6%	44.0%	90.3%	44.2%	44.0%
Other Female Genitals	70.2%	64.6%	71.5%	62.4%	57.0%	67.4%
Other invasive cancer	53.4%	46.5%	55.4%	42.6%	41.0%	47.1%
Other tumours	58.9%	52.0%	60.1%	67.4%	21.0%	59.5%
Prostate	18.9%	12.8%	20.4%	12.2%	6.0%	12.5%
Thyroid & other endocrine glands	80.6%	66.3%	83.7%	74.5%	22.5%	84.5%
Trachea, Bronchus & Lung	24.1%	15.1%	26.9%	12.4%	9.2%	12.0%
Upper GI	35.8%	31.1%	38.7%	13.2%	46.2%	26.2%

Showing 1 to 26 of 26 entries

Previous1Next

% of Cases treated with Radiotherapy

Show entries

Search:

	UKIACR average (population)	UKIACR average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	19.3%	19.9%	19.4%	17.8%	22.5%	19.7%
All xnmsc 0-24	15.1%	15.4%	15.0%	17.8%	14.8%	14.0%
All xnmsc 25-59	23.7%	25.3%	23.4%	24.3%	27.6%	25.7%
All xnmsc 60-79	21.2%	21.6%	21.3%	18.7%	25.2%	21.2%
All xnmsc 80+	10.8%	10.2%	11.0%	8.7%	10.2%	10.8%
Bladder	18.6%	19.0%	18.5%	17.6%	18.3%	21.7%
Brain and CNS	45.3%	45.2%	45.2%	45.7%	42.3%	47.6%
Breast	33.0%	34.6%	32.8%	34.2%	39.7%	31.8%
Breast in situ	26.4%	30.3%	25.7%	31.9%	43.8%	19.7%
Cervix	42.5%	49.0%	41.0%	49.2%	58.9%	46.9%
Cervix in situ	0.0%	0.1%	0.0%	0.0%	0.3%	0.0%
CUP	9.4%	10.5%	9.2%	9.4%	14.4%	9.1%
Haematology	9.2%	7.7%	9.5%	8.8%	4.5%	7.9%
Head and Neck	58.9%	58.6%	59.9%	46.3%	61.8%	66.5%
HPB	2.7%	2.4%	2.8%	1.4%	2.5%	3.1%
Kidney	6.5%	7.3%	6.4%	6.9%	7.8%	8.0%
Lower GI	12.9%	13.3%	12.8%	12.5%	14.2%	13.5%
Melanoma of skin	1.2%	0.9%	1.3%	0.3%	0.9%	0.9%
Non-Melanoma Skin Cancer	1.6%	1.3%	1.7%	0.7%	1.5%	1.4%
Other Female Genitals	15.1%	18.1%	14.4%	15.8%	20.3%	21.8%
Other invasive cancer	14.5%	15.2%	14.5%	12.6%	17.0%	16.8%
Other tumours	1.0%	0.9%	1.1%	0.2%	1.5%	0.7%
Prostate	17.7%	16.4%	18.8%	6.4%	26.4%	14.2%
Thyroid & other endocrine glands	24.6%	23.0%	25.2%	17.2%	26.3%	23.6%
Trachea, Bronchus & Lung	25.5%	26.1%	25.4%	25.9%	29.0%	24.3%
Upper GI	19.0%	17.7%	19.7%	11.2%	15.4%	24.3%

Showing 1 to 26 of 26 entries

Previous1Next

% of Cases treated with Teletherapy

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	18.1%	18.4%	18.2%	14.9%	21.5%	19.1%
All xnmsc 0-24	11.9%	11.7%	12.0%	10.8%	14.8%	9.3%
All xnmsc 25-59	21.9%	23.3%	21.8%	20.4%	26.0%	25.1%
All xnmsc 60-79	19.9%	20.1%	20.1%	15.7%	24.0%	20.5%
All xnmsc 80+	10.3%	9.7%	10.5%	7.5%	10.2%	10.7%
Bladder	18.3%	18.6%	18.4%	16.1%	18.3%	21.7%
Brain and CNS	43.8%	41.1%	44.8%	30.9%	42.3%	46.6%
Breast	32.4%	33.9%	32.2%	32.1%	39.6%	31.8%
Breast in situ	26.4%	30.2%	25.7%	31.6%	43.8%	19.7%
Cervix	40.7%	41.2%	40.3%	42.1%	35.6%	46.9%
Cervix in situ	0.0%	0.1%	0.0%	0.0%	0.3%	0.0%
CUP	9.0%	10.0%	9.0%	7.5%	14.4%	9.1%
Haematology	8.8%	7.4%	9.0%	8.2%	4.5%	7.9%
Head and Neck	57.3%	55.1%	59.5%	32.8%	61.8%	66.5%
HPB	2.1%	2.2%	2.2%	1.2%	2.2%	3.1%
Kidney	5.6%	6.9%	5.4%	6.6%	7.8%	8.0%
Lower GI	12.5%	12.6%	12.6%	10.2%	14.1%	13.5%
Melanoma of skin	1.1%	0.8%	1.2%	0.3%	0.9%	0.9%
Non-Melanoma Skin Cancer	1.6%	1.3%	1.7%	0.6%	1.5%	1.4%
Other Female Genitals	9.3%	11.6%	8.9%	7.3%	14.0%	16.0%
Other invasive cancer	10.8%	11.7%	10.9%	7.8%	17.0%	10.9%
Other tumours	0.8%	0.8%	0.9%	0.1%	1.5%	0.6%
Prostate	16.2%	14.4%	17.2%	4.1%	22.5%	13.9%
Thyroid & other endocrine glands	7.3%	13.2%	6.5%	1.8%	26.3%	18.2%
Trachea, Bronchus & Lung	25.0%	25.6%	25.0%	24.2%	29.0%	24.3%
Upper GI	18.2%	17.1%	18.9%	9.9%	15.4%	24.3%

Showing 1 to 26 of 26 entries

Previous1Next

% of Cases treated with Chemotherapy

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	25.6%	25.0%	25.9%	22.0%	25.5%	26.8%
All xnmsc 0-24	64.9%	59.5%	66.1%	59.8%	53.7%	58.1%
All xnmsc 25-59	40.5%	41.6%	40.2%	39.8%	41.4%	45.0%
All xnmsc 60-79	26.0%	25.1%	26.5%	21.0%	25.4%	27.4%
All xnmsc 80+	7.8%	6.4%	8.2%	4.4%	6.0%	7.1%
Bladder	26.6%	27.5%	26.7%	22.6%	28.9%	31.7%
Brain and CNS	35.0%	32.1%	35.5%	35.3%	28.2%	29.6%
Breast	32.5%	32.6%	32.4%	31.7%	31.8%	34.5%
Breast in situ	1.7%	1.8%	1.7%	0.3%	4.6%	0.4%
Cervix	39.6%	41.5%	38.9%	44.7%	42.5%	40.0%
Cervix in situ	0.0%	0.1%	0.0%	0.0%	0.3%	0.0%
CUP	7.9%	9.3%	7.9%	8.8%	15.5%	5.2%
Haematology	52.2%	49.6%	52.6%	50.7%	43.9%	51.2%
Head and Neck	28.7%	26.7%	29.3%	23.5%	20.6%	33.4%
HPB	23.4%	21.2%	24.2%	16.6%	23.4%	20.8%
Kidney	9.3%	10.8%	9.3%	4.2%	12.8%	16.7%
Lower GI	30.8%	31.2%	31.0%	26.3%	34.2%	33.3%
Melanoma of skin	3.8%	3.9%	3.9%	0.5%	4.0%	7.4%
Non-Melanoma Skin Cancer	0.2%	0.5%	0.1%	0.9%	1.0%	0.1%
Other Female Genitals	29.2%	27.3%	29.5%	29.5%	24.5%	25.5%
Other invasive cancer	26.5%	26.1%	26.6%	24.7%	26.7%	26.4%
Other tumours	12.2%	10.2%	12.5%	14.1%	4.4%	9.9%
Prostate	5.6%	6.2%	5.6%	2.2%	8.2%	8.9%
Thyroid & other endocrine glands	3.4%	7.3%	2.9%	4.4%	3.8%	18.2%
Trachea, Bronchus & Lung	22.4%	22.0%	23.1%	15.0%	24.2%	25.7%
Upper GI	38.2%	38.0%	38.5%	34.0%	40.3%	39.1%

Showing 1 to 26 of 26 entries

Previous1Next

% of Cases for other treatments

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
% of Cases treated with Hormone Therapy
All invasive xnmsc	12.9%	14.6%	12.5%	16.2%	18.4%	11.4%
Breast	39.9%	50.0%	36.8%	64.6%	67.3%	31.3%
Prostate	51.6%	52.7%	51.4%	54.7%	56.4%	48.3%
% of Cases treated with Brachytherapy
All invasive xnmsc	1.2%	0.9%	1.2%	0.5%	1.0%	0.9%
Breast	0.2%	0.1%	0.2%	0.0%	0.1%	0.0%
Prostate	1.6%	1.7%	1.6%	0.8%	3.8%	0.4%
% of Cases treated with Watch & Wait/Active Monitoring
All invasive xnmsc	8.1%	6.4%	8.6%	4.3%	4.1%	8.8%
Prostate	25.9%	19.2%	27.5%	16.8%	9.2%	23.5%
% of Cases treated with Palliative Care
All invasive xnmsc	9.3%	7.2%	10.1%	2.6%	7.8%	8.2%

Specific cohorts where treatment completeness data is expected (%)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
% of all haematological cancer patients who received any treatment	80.3%	76.5%	80.4%	88.2%	61.9%	75.4%
% of all stage 1 cancer patients who received any treatment	93.6%	90.5%	94.0%	91.5%	78.4%	98.2%
% of children and young adults (0-24 group) with cancer & underwent any treatment	94.6%	90.0%	95.3%	96.9%	75.9%	91.9%
% of men under 60 with prostate cancer & received hormone treatment	29.8%	32.4%	29.5%	29.6%	43.8%	26.6%
% of women under 60 with breast cancer & received hormone treatment	27.0%	37.4%	23.8%	53.3%	57.3%	15.2%

Showing 1 to 5 of 5 entries

Previous1Next

Quality of treatment data

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
Surgery (denominator - all tumours known to be treated with surgery, first recorded surgery for that tumour):
Date of surgery known	99.7%	99.9%	99.7%	100.0%	100.0%	100.0%
Trust / hospital of surgery known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Type of surgery known (OPCS4 code)	92.8%	74.5%	100.0%	0.0%	100.0%	98.1%
Teletherapy (denominator - all tumours known to be treated with teletherapy , first recorded teletherapy treatment for that tumour):
Date of teletherapy known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Trust / hospital of teletherapy known	99.9%	99.4%	100.0%	100.0%	97.5%	100.0%
Fractions and dose known	89.8%	73.1%	96.7%	0.0%	97.5%	98.4%
Chemotherapy (denominator - all tumours known to be treated with chemotherapy, first recorded chemotherapy treatment for that tumour):
Date of chemotherapy known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Trust / hospital of chemotherapy known	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Drug name or regimen known	75.8%	46.6%	86.5%	0.0%	100.0%	0.0%
Radiotherapy (denominator - all tumours known to be treated with radiotherapy, take the first recorded radiotherapy event for that tumour):
Date of radiotherapy known	100.0%	99.9%	100.0%	100.0%	99.4%	100.0%
Trust / hospital of radiotherapy known	99.9%	99.0%	100.0%	100.0%	96.0%	100.0%

Breast cancer screening completeness (%)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
Breast cancer - % screen detected for ages 50-64 (data 2020)	27.1%	36.5%	24.5%	38.1%	44.6%	38.7%
Breast cancer - % screen detected for ages 50-64 (last year, 2019)	50.5%	51.4%	50.3%	50.4%	49.7%	55.1%
Breast cancer - % with full screening history for ages 50-64 (data 2020)	74.2%	78.5%	71.8%	99.9%	-	63.8%
Breast cancer - % with full screening history for ages 50-64 (last year, 2019)	97.6%	89.9%	98.9%	99.9%	-	70.9%

Showing 1 to 4 of 4 entries

Previous1Next

Cervical cancer screening completeness (%)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
Cervical cancer - % screen detected for ages 25-60 (data 2020)	7.5%	31.3%	1.3%	38.1%	46.3%	39.3%
Cervical cancer - % screen detected for ages 25-60 (last year, 2019)	20.4%	44.2%	13.5%	54.3%	63.1%	45.9%
Cervical cancer - % with full screening history for ages 25-60 (data 2020)	18.6%	49.1%	8.6%	100.0%	-	38.9%
Cervical cancer - % with full screening history for ages 25-60 (last year, 2019)	43.1%	60.7%	36.0%	100.0%	-	45.9%

Showing 1 to 4 of 4 entries

Previous1Next

Bowel cancer screening completeness (%)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
Bowel cancer - % screen detected for ages 60-69 (data 2020)	3.8%	16.9%	0.0%	23.2%	19.3%	25.2%
Bowel cancer - % screen detected for ages 60-69 (last year, 2019)	5.8%	22.1%	0.0%	37.1%	26.6%	24.9%
Bowel cancer - % with full screening history for ages 60-69 (data 2020)	9.8%	41.7%	0.0%	100.0%	-	25.1%
Bowel cancer - % with full screening history for ages 60-69 (last year, 2019)	11.6%	41.7%	0.0%	99.8%	-	25.1%

Showing 1 to 4 of 4 entries

Previous1Next

Completeness of the dataset (%) - stage complete by cancer site groups summary (persons)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	75.1%	75.8%	75.5%	66.4%	81.2%	80.0%
Bladder	76.5%	79.5%	76.6%	66.4%	90.4%	84.6%
Brain	0.6%	0.3%	0.7%	0.0%	0.0%	0.7%
Breast	86.0%	88.0%	85.9%	84.2%	96.6%	85.2%
Bronchus & Lung	90.7%	92.3%	90.2%	92.0%	94.4%	92.5%
Cervix	87.9%	92.3%	86.9%	90.6%	97.3%	94.6%
CUP	49.5%	39.6%	55.7%	0.0%	50.0%	52.6%
Haematology	54.4%	46.5%	58.2%	0.0%	54.4%	73.3%
Head and Neck	84.9%	87.0%	85.3%	75.4%	94.4%	92.7%
HPB	68.4%	70.9%	68.2%	66.4%	76.9%	72.1%
Kidney	78.3%	83.9%	77.4%	79.2%	93.6%	85.5%
Lower GI	84.2%	83.7%	85.1%	68.5%	89.7%	91.4%
Melanoma	85.5%	80.5%	88.0%	54.5%	86.4%	93.3%
Non Melanoma skin	1.4%	5.0%	1.5%	0.0%	16.8%	1.5%
Other Female Genitals	80.3%	82.8%	80.4%	71.4%	91.2%	88.1%
Other invasive cancer	54.1%	45.8%	57.5%	23.0%	46.6%	56.0%
Prostate	84.2%	85.8%	84.1%	78.4%	89.7%	90.9%
Thyroid and other endocrine glands	65.8%	70.4%	64.8%	70.4%	74.3%	71.9%
Upper GI	74.0%	76.5%	73.5%	72.5%	77.2%	82.7%

Showing 1 to 19 of 19 entries

Previous1Next

Completeness of the dataset (%) - grade complete by cancer site groups summary (persons)

Show entries

Search:

	Country average (population)	Country average (country)	England	Scotland	Northern Ireland	Wales
All invasive xnmsc	56.1%	57.3%	55.9%	57.3%	59.6%	56.5%
All registrations	43.8%	45.3%	43.3%	47.3%	45.5%	45.1%
All xnmsc 0-24	27.7%	37.4%	25.2%	47.5%	47.2%	29.7%
All xnmsc 25-59	65.5%	67.8%	64.8%	69.8%	69.4%	67.2%
All xnmsc 60-79	60.8%	61.5%	60.7%	61.3%	63.0%	61.2%
All xnmsc 80+	37.1%	37.0%	37.3%	34.5%	40.0%	36.3%
Bladder	79.6%	81.9%	79.3%	78.0%	87.2%	82.9%
Brain and CNS	65.4%	58.0%	67.1%	63.0%	55.7%	46.3%
Breast	95.5%	95.7%	95.4%	96.2%	95.8%	95.2%
Cervix	82.6%	78.3%	83.2%	82.3%	63.0%	84.6%
CUP	19.6%	17.6%	19.9%	19.3%	12.2%	19.1%
Haematology	18.0%	36.8%	13.9%	47.2%	72.8%	13.3%
Head and Neck	74.2%	77.9%	73.4%	74.6%	81.4%	82.1%
HPB	27.4%	23.9%	28.5%	20.2%	24.5%	22.3%
Kidney	53.4%	53.7%	53.4%	52.4%	55.1%	53.8%
Lower GI	75.8%	74.8%	76.0%	75.4%	72.9%	75.0%
Melanoma of skin	0.4%	0.3%	0.4%	0.7%	0.0%	0.1%
Other Female Genitals	76.0%	76.4%	76.1%	72.4%	78.4%	78.8%
Other invasive cancer	29.6%	29.1%	30.0%	26.9%	31.9%	27.5%
Prostate	78.2%	78.2%	78.1%	78.8%	75.7%	80.1%
Thyroid and other endocrine glands	18.2%	16.5%	18.2%	28.5%	3.8%	15.5%
Trachea, Bronchus & Lung	21.8%	21.7%	21.5%	23.3%	16.2%	25.7%
Upper GI	72.4%	73.1%	72.4%	71.2%	76.1%	72.5%

Showing 1 to 23 of 23 entries

Previous1Next

This site (ukiacr.org) uses cookies in order to enhance your user experience